Unknown

Dataset Information

0

Chronic Verubecestat Treatment Suppresses Amyloid Accumulation in Advanced Aged Tg2576-A?PPswe Mice Without Inducing Microhemorrhage.


ABSTRACT: Verubecestat is a potent BACE1 enzyme inhibitor currently being investigated in Phase III trials for the treatment of mild-to-moderate and prodromal Alzheimer's disease. Multiple anti-amyloid immunotherapies have been dose-limited by adverse amyloid related imaging abnormalities such as vasogenic edema (ARIA-E) and microhemorrhage (ARIA-H) observed in human trials and mice. Verubecestat was tested in a 12-week nonclinical study for the potential to exacerbate microhemorrhage (ARIA-H) profiles in 18-22-month-old post-plaque Tg2576-A?PPswe mice. Animals were treated with verubecestat or controls including the anti-A? antibody analog of bapineuzumab (3D6) as a positive control for ARIA induction. ARIA-H was measured using in-life longitudinal T2*-MRI and Prussian blue histochemistry at study end. Verubecestat reduced plasma and cerebrospinal fluid A?40 and A?42 by?>90% and 62% to 68%, respectively. The ARIA-H profile of verubecestat-treated mice was not significantly different than controls. Anti-A? treatment significantly increased ARIA-H detected by Prussian blue staining; however, anti-A? antibody treatment did not impact plaque status. Verubecestat treatment significantly suppressed the accumulation of total levels of brain A?40 and A?42 and Thioflavin S positive plaque load. Stereological analysis of cortex and hippocampus plaque load similarly revealed significantly reduced area of A? immunoreactivity and reduced plaque number in verubecestat-treated animals compared to controls. The absence of elevated ARIA events in verubecestat-treated mice was associated with a significant reduction in the level of accumulated CNS amyloid pathology and brain A? peptides; effects consistent with the desired therapeutic mechanism of verubecestat in AD patients. These data will be compared with longitudinal MRI profiles from ongoing clinical trials.

SUBMITTER: Villarreal S 

PROVIDER: S-EPMC5611839 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature

altmetric image

Publications

Chronic Verubecestat Treatment Suppresses Amyloid Accumulation in Advanced Aged Tg2576-AβPPswe Mice Without Inducing Microhemorrhage.

Villarreal Stephanie S   Zhao Fuqiang F   Hyde Lynn A LA   Holder Daniel D   Forest Thomas T   Sondey Marie M   Chen Xia X   Sur Cyrille C   Parker Eric M EM   Kennedy Matthew E ME  

Journal of Alzheimer's disease : JAD 20170101 4


Verubecestat is a potent BACE1 enzyme inhibitor currently being investigated in Phase III trials for the treatment of mild-to-moderate and prodromal Alzheimer's disease. Multiple anti-amyloid immunotherapies have been dose-limited by adverse amyloid related imaging abnormalities such as vasogenic edema (ARIA-E) and microhemorrhage (ARIA-H) observed in human trials and mice. Verubecestat was tested in a 12-week nonclinical study for the potential to exacerbate microhemorrhage (ARIA-H) profiles in  ...[more]

Similar Datasets

| S-EPMC4345564 | biostudies-literature
| S-EPMC1892920 | biostudies-literature
| S-EPMC2647980 | biostudies-literature
| S-EPMC5325834 | biostudies-literature
| S-EPMC7084806 | biostudies-literature
2017-11-02 | PXD007795 | Pride
| S-EPMC3488119 | biostudies-literature
| S-EPMC6319729 | biostudies-literature
| S-EPMC7747164 | biostudies-literature
| S-EPMC8412093 | biostudies-literature